Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ramucirumab”

147 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 147 results

Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Testing effectiveness (Phase 2)WithdrawnNCT05007769
What this trial is testing

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

Who this might be right for
Non-small Cell Lung CancerNon-small Cell CarcinomaNSCLC+1 more
Washington University School of Medicine
Testing effectiveness (Phase 2)Study completedNCT02443883
What this trial is testing

Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 164
Early research (Phase 1)UnknownNCT02970539
What this trial is testing

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Who this might be right for
Gastric CancerEsophageal CancerGastro-esophageal Cancer
Athenex, Inc. 36
Large-scale testing (Phase 3)Study completedNCT01168973
What this trial is testing

Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 1,253
Early research (Phase 1)Study completedNCT02745769
What this trial is testing

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Who this might be right for
Advanced CancerColorectal CancerMantle Cell Lymphoma
Eli Lilly and Company 23
Large-scale testing (Phase 3)Study completedNCT01170663
What this trial is testing

Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Who this might be right for
Gastric Cancer
Eli Lilly and Company 665
Testing effectiveness (Phase 2)Study completedNCT01515306
What this trial is testing

Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Who this might be right for
Malignant Solid Tumor
Eli Lilly and Company 48
Testing effectiveness (Phase 2)Looking for participantsNCT05927857
What this trial is testing

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Who this might be right for
Metastatic Gastric AdenocarcinomaSecond LineChemotherapy
National Health Research Institutes, Taiwan 45
Testing effectiveness (Phase 2)Study completedNCT00515697
What this trial is testing

Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell Carcinoma
Eli Lilly and Company 39
Testing effectiveness (Phase 2)Looking for participantsNCT04205968
What this trial is testing

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Who this might be right for
Metastatic Small Intestinal AdenocarcinomaStage III Small Intestinal Adenocarcinoma AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8+2 more
SWOG Cancer Research Network 94
Not applicableApproved For MarketingNCT02065765
What this trial is testing

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerMetastatic Adenocarcinoma of the Gastroesophageal Junction
Eli Lilly and Company
Large-scale testing (Phase 3)Study completedNCT02661971
What this trial is testing

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

Who this might be right for
Stomach CancerGastroesophageal Junction Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT02711553
What this trial is testing

Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerMetastatic CancerAdvanced Cancer
Eli Lilly and Company 309
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06441019
What this trial is testing

Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab
Fudan University 42
Testing effectiveness (Phase 2)Study completedNCT01427933
What this trial is testing

Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 141
Testing effectiveness (Phase 2)WithdrawnNCT03739801
What this trial is testing

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced Unresectable Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Unresectable Gastric Adenocarcinoma+3 more
University of Southern California
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06904300
What this trial is testing

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Who this might be right for
Gastric (Cardia, Body) Cancer
Sun Yat-sen University 110
Testing effectiveness (Phase 2)Looking for participantsNCT06031688
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
SWOG Cancer Research Network 56
Large-scale testing (Phase 3)Active Not RecruitingNCT05633602
What this trial is testing

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
SWOG Cancer Research Network 838
Load More Results